Attenuated Salmonella engineered to produce human cytokine LIGHT inhibit tumor growth
Open accessThe DOI matches its Crossref record.
Abstract
Intravenously administered bacteria reportedly accumulate in tumors. Furthermore, systemic administration of attenuated Salmonella typhimurium has little or no significant side-effects in humans. Consequently, we engineered such bacteria to improve their oncolytic activity by stably inserting a gene encoding LIGHT, a cytokine known to promote tumor rejection. Unlike control bacteria, attenuated S. typhimurium expressing LIGHT inhibited growth of primary tumors, as well as the dissemination of pulmonary metastases, in various mouse tumor models employing murine carcinoma cell lines in immunocompetent mice. Antitumor activity was achieved without significant toxicity and was associated with infiltration of inflammatory cells and dependent on the LIGHT receptors, herpes virus entry mediator (HVEM), and lymphotoxin-β receptor (LTβR). These findings provide evidence that nonvirulent bacteria can be exploited as targeting vehicles for local generation of therapeutic proteins in tumors.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Engineering the perfect (bacterial) cancer therapy
Forbes, N. S. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2934 · Cited by 905
Biomedical Applications of Untethered Mobile Milli/Microrobots
Sitti, M., Ceylan, H., Hu, W., Giltinan, J., Turan, M., Yim, S., & Diller, E. (2015) · Proceedings of the IEEE · doi:10.1109/jproc.2014.2385105 · Cited by 893
Tumour-targeting bacteria engineered to fight cancer
Zhou, S., Gravekamp, C., Bermudes, D., & Liu, K. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0070-z · Cited by 821
Zheng, J. H., Nguyen, V. H., Jiang, S.-N., Park, S.-H., Tan, W., Hong, S. H., Shin, M. G., Chung, I.-J., Hong, Y., Bom, H.-S., et al. (2017) · Science Translational Medicine · doi:10.1126/scitranslmed.aak9537 · Cited by 588
“Although these strategies resulted in improved therapeutic effects, they still have limitations; for example, multiple injections of bacteria are required, and tumors tend to recur (20, 23, 24).”
BackgroundEngineering bacteria for diagnostic and therapeutic applications
Riglar, D. T., & Silver, P. A. (2018) · Nature Reviews Microbiology · doi:10.1038/nrmicro.2017.172 · Cited by 460
(2023) · doi:10.1038/s41392-022-01304-4 · Cited by 460
Bioengineered and biohybrid bacteria-based systems for drug delivery
Hosseinidoust, Z., Mostaghaci, B., Yasa, O., Park, B.-W., Singh, A. V., & Sitti, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.09.007 · Cited by 368
Bacteria in cancer therapy: a novel experimental strategy
Patyar, S., Joshi, R., Byrav, D. P., Prakash, A., Medhi, B., & Das, B. (2010) · Journal of Biomedical Science · doi:10.1186/1423-0127-17-21 · Cited by 340
Bacteria‐Based Cancer Immunotherapy
Huang, X., Pan, J., Xu, F., Shao, B., Wang, Y., Guo, X., & Zhou, S. (2021) · Advanced Science · doi:10.1002/advs.202003572 · Cited by 304
Ectopic lymphoid tissues and local immunity
Carragher, D. M., Rangel-Moreno, J., & Randall, T. D. (2008) · Seminars in Immunology · doi:10.1016/j.smim.2007.12.004 · Cited by 274
Bacteria as vectors for gene therapy of cancer
Baban, C. K., Cronin, M., O’Hanlon, D., O’Sullivan, G. C., & Tangney, M. (2010) · Bioengineered Bugs · doi:10.4161/bbug.1.6.13146 · Cited by 175
Zhang, Y., Zhang, Y., Xia, L., Zhang, X., Ding, X., Yan, F., & Wu, F. (2012) · Applied and Environmental Microbiology · doi:10.1128/aem.01390-12 · Cited by 138
Targeted cancer immunotherapy with genetically engineered oncolytic Salmonella typhimurium
Guo, Y., Chen, Y., Liu, X., Min, J.-J., Tan, W., & Zheng, J. H. (2020) · Cancer Letters · doi:10.1016/j.canlet.2019.10.033 · Cited by 124
Metadata
- Authors
- Loeffler, M., Le'Negrate, G., Krajewska, M., & Reed, J. C.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2007-07-31
- Volume
- 104
- Issue
- 31
- Pages
- 12879-12883
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2077530057
- Cited by
- 180
- References
- 0
- FWCI
- 7.30
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.